HDAC9 and head and neck squamous cell carcinoma: Here, we use TSA and PXD101 to demonstrate that HDAC inhibitors have the potential to induce repression of HNSCC aggressiveness and to inactivate ADP-ribosylation factor 1 (Arf1), a small GTPase involved in regulation of membrane trafficking pathways [15–17].